Amendments to the Claims

Without prejudice or disclaimer, this listing of claims will replace all prior versions and listing of claims in this application.

1. (Presently amended) A compound of formula I:



I;

wherein:

m, q and r are independently 0, 1 or 2;

n is 0 or 1;

R is H or COR^2;

R^0 is independently at each occurrence OH, CF_3, halo, C_1-C_6 alkyl or C_1-C_6 alkoxy;

R^1 and $R^{1'}$ are independently C_1-C_6 alkyl, C_1-C_6 alkoxy, NR^3R^{3a}, CF_3 or CH_2CF_3; or when n and q are 0, the $-SO_2R^1$ moiety may combine with the phenyl ring to which it is attached to form a moiety of formula (a) or (b):



(a) (b);

wherein t and v are 0, 1 or 2 provided that the sum of t + v must be 2;

R^2 is C_1-C_6 alkyl; C_1-C_6 alkoxy; NR^4R^4; phenoxy; or phenyl optionally substituted with halo;

R^3 is C_1-C_6 alkyl or phenyl;

R^{3a} and R^4 are independently at each occurrence H, C_1-C_6 alkyl, or phenyl;

X is O, CH_2 or CO;

X^1 is O or NR^5;

R^5 is H or C_1-C_6 alkyl; ~~and~~

R^8 is H or methyl provided that if r is 1 or 2, then R^8 must be H and that if r is 0, then R^8 must be methyl; and

Y is S, CH_2CH_2 or CH=CH; or a pharmaceutical acid addition salt thereof.

2. (Original) The compound of claim 1 wherein m is 2; and r is 1 or 2; or a pharmaceutical acid addition salt thereof.

3. (Presently amended) The compound of claim ~~1 or~~ 2 wherein R^2 is C_1-C_6 alkyl, $NHCH_3$ or phenyl and the $-SO_2R^1$ moiety does not combine with the phenyl ring to which it is attached to form a moiety of formula (a) or (b); or a pharmaceutical acid addition salt thereof.

4. (Presently amended) The compound of ~~any one of claims 1-3~~ **claim 3** wherein n is 0; q is 0 or 1; the $-SO_2R^1$ moiety is at the para-position of the phenyl ring to which it is attached; R^0 is OH, CF_3, fluoro, chloro, methyl or ethyl; R^1 is methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclobutyl or CF_3; R^2 is C_1-C_6 alkyl or phenyl; and Y is S or CH=CH; or a pharmaceutical acid addition salt thereof.

5. (Presently amended) The compound of ~~any one of claims 1-4~~ **claim 4** wherein X and X^1 are O; or a pharmaceutical acid addition salt thereof.

6. (Presently amended) The compound of ~~any one of claims 1-5~~ **claim 5** wherein q is 0; R^1 is methyl, ethyl, cyclopropyl or CF_3; and Y is CH=CH; or a pharmaceutical acid addition salt thereof.

7. (Presently amended) The compound of ~~any one of claims 1-6~~ **claim 6 wherein R is H** ~~selected from the group consisting of:~~



;

or a pharmaceutical acid addition salt thereof.

8. (Presently amended) The compound **of claim 7** which is:



;

or a pharmaceutical acid addition salt thereof.

9. (Presently amended) The compound **of claim 7** which is:



;

or a pharmaceutical acid addition salt thereof.

10. (Presently amended) The compound **of claim 6** which is:



;

or a pharmaceutical acid addition salt thereof.

11. (Presently amended) The compound **of claim 6** which is:



;

or a pharmaceutical acid addition salt thereof.

12. (Presently amended) The compound **of claim 7** which is:



;

or a pharmaceutical acid addition salt thereof.

13. (Presently amended) The compound **of claim 7** which is:



;

or a pharmaceutical acid addition salt thereof.

14. (Presently Amended) The compound of ~~any one of claims 1-13~~ **claim 8** which is the hydrochloride salt.

15. (Presently Amended) A method of treating endometriosis comprising administering to a patient in need thereof an effective amount of a compound of ~~any one of claims 1-14~~ **claim 8**, or a pharmaceutical acid addition salt thereof.

16. (Presently Amended) A method of treating uterine leiomyoma comprising administering to a patient in need thereof an effective amount of a compound of ~~any one of claims 1-14~~ **claim 8**, or a pharmaceutical acid addition salt thereof.

17. Cancelled

18. (Original) A compound of formula II:



II;

wherein:

m, q, r and u are independently 0, 1 or 2;

n is 0 or 1;

R^0 is independently at each occurrence OH, CF_3, halo, C_1-C_6 alkyl or C_1-C_6 alkoxy;

R^1 and $R^{1'}$ are independently C_1-C_6 alkyl, C_1-C_6 alkoxy, NR^3R^{3a}, CF_3 or CH_2CF_3; or when n and q are 0, the $-SO_uR^1$ moiety may combine with the phenyl ring to which it is attached to form a moiety of formula (c) or (d):



(c) (d);

wherein t and v are 0, 1 or 2 provided that the sum of t + v must be 2;

R^2 is C_1-C_6 alkyl; C_1-C_6 alkoxy; NR^4R^4; phenoxy; or phenyl optionally substituted with halo;

R^3 is C_1-C_6 alkyl or phenyl;

R^{3a} and R^4 are independently at each occurrence H, C_1-C_6 alkyl or phenyl;

R^6 is H, C_1-C_6 alkyl, benzyl or COR^2;

R^7 is H, C_1-C_6 alkyl or CO_2(C_1-C_6 alkyl);

R^8 is H or methyl provided that if r is 1 or 2, then R^8 must be H and that if r is 0, then R^8 must be methyl;

X is O, CH_2 or CO;

X^2 is O or NR^7;

Y is S, CH_2CH_2 or CH=CH; or a pharmaceutical acid addition salt thereof; provided that u can only be 2 when R^6 is C_1-C_6 alkyl or benzyl; or an acid addition salt thereof; and further provided that the compound of formula II is not:



19. (Original) The compound of claim 18, or an acid addition salt thereof, wherein r is 1 or 2; and

a) if n is 0 and the SO_uR^1 moiety and R^0 combine with the phenyl ring to which they are both attached to form a moiety of formula (c) or (d), then u is 2; and

b) if n is 1, then m and u are both 0, are both 1 or are both 2.

20. (Presently amended) The compound of ~~claim 18 or~~ 19 wherein the -SO_uR^1 moiety does not combine with the phenyl ring to which it is attached to form a moiety of formula (c) or (d) and is at the para-position of said phenyl ring to which it is attached; n is 0; q is 0 or 1; R^0 is OH, CF_3, fluoro, chloro, methyl or ethyl; R^1 is methyl, ethyl, n-propyl,

isopropyl, cyclopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, cyclobutyl or CF_3; R^2 is C_1-C_6 alkyl or phenyl; X and X^1 are O; and Y is S or CH=CH; or an acid addition salt thereof.

21. (Presently amended) The compound of ~~any one of claims 18-20~~ **claim 20** wherein q is 0; R^1 is methyl, ethyl, cyclopropyl or CF_3; and Y is CH=CH; or an acid addition salt thereof.

22. (Presently amended) The compound of ~~any one of claims 18-21 selected from the group consisting of~~ **claim 20 which is**:



;

or an acid addition salt thereof.

23. (New) The method of claim 15 wherein the compound is the hydrochloride salt.

24. (New) The method of claim 16 wherein the compound is the hydrochloride salt.

25. (New) The compound of claim 7 which is:



;

or a pharmaceutical acid addition salt thereof.

Respectfully submitted,



Gilbert T. Voy
Attorney for Applicant
Registration No. 43,972
Phone: 317-276-2966

Eli Lilly and Company
Patent Division/GTV
Lilly Corporate Center
Indianapolis, Indiana 46285

January 11, 2005